McMaster University Medical School

Tremeau Pharmaceuticals to Host Key Opinion Leader Webinar on Rofecoxib in Migraine Management on Tuesday, October 25th

Retrieved on: 
Thursday, October 20, 2022
Pharmaceutical, Health, Neurology, Feinberg School of Medicine, Bureau of Oceans and International Environmental and Scientific Affairs, Migraine, Risk, Practical Management of Pain, VP, Albany Medical Center, Traffic barrier, International Association for the Study of Pain, Bleeding time, Nonsteroidal anti-inflammatory drug, McMaster University Medical School, Pain management, Internal medicine, Chronic pain, History, Gastrointestinal bleeding, Trémeau, MD, National, Q&A, International Association, American Academy, Medication, KOL, NSAID, Stony Brook University, Albany Medical College, American Academy of Neurology, Pharmaceutical industry, Pain, Neurology

Dr. Argoff is one of the editors of the recently published textbook Raj's Practical Management of Pain, 6th Edition.

Key Points: 
  • Dr. Argoff is one of the editors of the recently published textbook Raj's Practical Management of Pain, 6th Edition.
  • In addition, Tremeaus Founder and CEO Bradford C. Sippy will discuss the companys development pipeline, including Phase III-ready TRM-201 (rofecoxib).
  • Previously marketed as VIOXX, rofecoxib has been shown to have a well-established efficacy profile in multiple indications, including migraine.
  • Tremeaus lead clinical stage product, TRM-201 (rofecoxib), is a COX-2 selective NSAID and a potent non-opioid analgesic with a well-established benefit-risk profile.

WELL Health to Acquire EMR, Billing and Clinical Assets from CloudMD

Retrieved on: 
Tuesday, October 11, 2022
Cloud, OSCAR McMaster, Physician, TSX, McMaster University, Health, Patient, Transaction, Blackwell, WELL, US Bankcard Services Inc, Technology, Acquisition, Industry, Department, Founder, CEO, EMR, McMaster University Medical School, Electronic health record, OSCAR, Property management, Medicine, BC

Post transaction WELL expects the assets to operate profitably while contributing more than $9M in topline revenues.

Key Points: 
  • Post transaction WELL expects the assets to operate profitably while contributing more than $9M in topline revenues.
  • WELL will pay approximately $5.75 million for all assets, subject to post-closing adjustments and holdbacks, reflecting an accretive transaction.
  • Both assets will be integrated into WELL's Provider Solutions Business Unit, under WELL's existing EMR and Billing platforms.
  • These three clinics will be integrated into WELL's existing primary care clinic network under WELL Health Canada Clinics Inc.

Dr. Richard Heinzl, Physician, Humanitarian, Entrepreneur and Author, Appointed to Asep Inc.'s Board of Directors

Retrieved on: 
Thursday, September 29, 2022
People, Emeritus, Sinusitis, American College, Penguin Books, McMaster University Medical School, Sepsis, Intention, Company, News, Review, Forward-looking statement, Harvard University, 2017 Nobel Peace Prize, University, Risk, Physician, Disease, CEO, CSE, Global health, McMaster University, Throat, LLD, Solution, American College of Preventive Medicine, Diagnosis, Artificial intelligence, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Death, Lung, Nobel Peace Prize, Genomics, Overalls, Mortality, Skin, School, Global Medical Device Nomenclature, Multimedia, View, DeGroote School of Business, Medical device, Medicine, Pharmaceutical industry, ASEP, BC, Medicine

VANCOUVER, BC, Sept. 29, 2022 /PRNewswire/ -Asep Medical Holdings Inc. ("Asep Inc." or the"Company") (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce the appointment of Dr. Richard Heinzl to the Company's board of directors effective immediately.

Key Points: 
  • VANCOUVER, BC, Sept. 29, 2022 /PRNewswire/ -Asep Medical Holdings Inc. ("Asep Inc." or the"Company") (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce the appointment of Dr. Richard Heinzl to the Company's board of directors effective immediately.
  • Dr. Heinzl is a physician, humanitarian, entrepreneur and author whose current focus is genomics, artificial intelligence and healthcare worldwide.
  • Based in New York and Toronto, he is currently CEO of My Next Health Inc., a next-generation functional genomics company.
  • Dr. Heinzl stated, "I am very honoured to be part of the Asep team under Bob Hancock's visionary scientific leadership.

Versanis Bio Announces Leadership and Board Appointments as Company Prepares to Initiate Phase 2b Study with Novel Approach to Obesity

Retrieved on: 
Wednesday, July 20, 2022
Intercept, Body composition, University, Biogen, Weight, Obesity, Overweight, Wharton School of the University of Pennsylvania, Industry, Atlas, Myostatin, CEO, Executive, Lists of companies, Health, NASH, RNA interference, Intercept Pharmaceuticals, Board, Activin and inhibin, Type 2 diabetes, Wendell Pritchett, Atlas Venture, Biotechnology, DOV Pharmaceutical, Director, MBA, Chicago (franchise), Disease, Biochemistry, Patient, Liver failure, McMaster University Medical School, Doctor of Philosophy, Bimagrumab, Therapy, Chronic liver disease, Program, Ligand, Biotechnology Innovation Organization, International relations, Molecular biology, SAB, GDF11, Johns Hopkins University, BIO, Takeda Oncology, Management, Pharmaceutical industry, Dietary supplement, ZymoGenetics, Alnylam Pharmaceuticals

NEW YORK, July 20, 2022 /PRNewswire/ -- Versanis Bio ("Versanis"), a clinical-stage company advancing novel therapeutics for cardiometabolic diseases, today announced three organizational appointments. Versanis welcomes Mark Pruzanski, M.D., as Chairman and Chief Executive Officer, and John Maraganore, Ph.D., and Barbara Duncan, MBA, to the Board of Directors. Lloyd Klickstein, M.D., Ph.D., who co-founded the company in 2021 with Aditum Bio, will continue in the role of President and Chief Scientific Officer.

Key Points: 
  • NEW YORK, July 20, 2022 /PRNewswire/ -- Versanis Bio ("Versanis"), a clinical-stage company advancing novel therapeutics for cardiometabolic diseases, today announced three organizational appointments.
  • Versanis is advancing its lead asset bimagrumab, a first-in-class monoclonal antibody that binds activin type II receptors, into a Phase 2b study later this year for the initial indication of obesity.
  • Versanis is a privately held, clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease.
  • Versanis was founded in 2021 and is a portfolio company of Aditum Bio, Atlas Venture and Medicxi.

National Cancer Center Announces Recipients of 2022-23 Research Fellowship Awards

Retrieved on: 
Thursday, June 30, 2022
Science, Other Philanthropy, Research, Oncology, Health, Philanthropy, Fund Raising, Foundation, Melanoma, Diagnosis, New York University Grossman School of Medicine, University of Nebraska Medical Center, Rockefeller University, Research, Harvard Medical School, Icahn School of Medicine at Mount Sinai, National Cancer Center, Death, Man, Nebraska Medicine, NCC, Cancer, Brain, University of Pittsburgh, University of California, PAP, Prostate cancer, Coronavirus Scientific Advisory Board (Turkey), UPMC Hillman Cancer Center, Woman, Therapy, Dana–Farber Cancer Institute, Education, University, Cleveland Clinic, Duke University Hospital, City, DNA, Cervical cancer, McMaster University Medical School, Johns Hopkins School of Medicine, Time, DNA repair, Massachusetts General Hospital, Interferon, Baylor College of Medicine, Pharmaceutical industry, Management, Medicine, Doctor of Philosophy

The National Cancer Center is pleased to announce the recipients of its 2022-23 research grant awards, which support research fellows pursuing promising and innovative cancer research.

Key Points: 
  • The National Cancer Center is pleased to announce the recipients of its 2022-23 research grant awards, which support research fellows pursuing promising and innovative cancer research.
  • This growing public support also enabled National Cancer Center to increase the size of its awards by a significant margin.
  • National Cancer Centers mission is to fill an often-overlooked role in the quest to cure cancer by identifying and funding promising projects by the best up-and-coming research fellows, said Regina English, Executive Director of the National Cancer Center.
  • National Cancer Center was founded by Dr. J. Ernest Ayre in 1953 as a non-profit organization committed to research and education about cancer.

Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer

Retrieved on: 
Thursday, June 9, 2022
Biotechnology, Health, Optical, Toyota Aurion, Leadership, Eye, Company, Cornea, Ophthalmology, Feinberg School of Medicine, Corneal transplantation, Florida College, Williams College, Endothelial dysfunction, Nasdaq, University of Florida College of Medicine-Jacksonville, Multimedia, Cell, University, McMaster University Medical School, Patient, Endothelium, Visual acuity, Tufts University School of Medicine, Biotechnology, Pharmaceutical industry, Medical imaging

Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Michael Goldstein, M.D., M.B.A., as president and chief medical officer.

Key Points: 
  • Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Michael Goldstein, M.D., M.B.A., as president and chief medical officer.
  • Before joining Aurion Biotech, Dr. Goldstein served as president and chief medical officer of Ocular Therapeutix (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye.
  • Before joining AGTC, Dr. Goldstein held several positions of increasing responsibility with Eleven Biotherapeutics, including chief medical officer and vice president of clinical research.
  • The Aurion Biotech team is preparing for clinical trials in the U.S. To learn more about Aurion Biotech, visit www.aurionbiotech.com .

McMaster Innovation Park and IMPACT at UCalgary Announce MOU to Enhance Access to Clinical Trials for Life Sciences Ventures

Retrieved on: 
Monday, March 14, 2022
Heart, Government, IMPACT, McMaster University Medical School, University, List of life sciences, McMaster University, Research, Partnership, Engineering, MIP, University of Calgary, Board, Board of directors, MOU, Ecosystem, Director, Growth, McMaster Innovation Park, CEO, Pharmaceutical industry, Management

MOU to provide access to the leading-edge IMPACT clinical trial program, strategic support for life science ventures

Key Points: 
  • MOU to provide access to the leading-edge IMPACT clinical trial program, strategic support for life science ventures
    HAMILTON, ON, March 14, 2022 /CNW/ - For Life Sciences venture companies, health-related innovations ready for clinical trials are being accelerated, through a Memorandum of Understanding between McMaster Innovation Park (MIP) and the Integrated Management Platform to Accelerate Clinical Trials (IMPACT) at the University of Calgary (UCalgary).
  • The MOU facilitates access to the leading-edge IMPACT clinical trial program for MIP tenant life sciences ventures, while providing opportunities for growing UCalgary IMPACT ventures to advance toward commercialization and manufacturing at MIP.
  • IMPACT assists ventures with the timely initiation and completion of clinical trials vital to the licensing and commercialization of health-inventions in the domestic and international markets.
  • The IMPACT Venture Navigators work with the venture to design, support, execute, and report on their pre-market clinical trials for less capital.

Dr. Mahmud Kara is recognized by Continental Who's Who

Retrieved on: 
Monday, February 21, 2022
University Hospitals Portage Medical Center, Case Western Reserve University School of Medicine, McMaster University Medical School, Cleveland Clinic, ESRD, University, American Academy, Industry, American Medical Association, Organization, Medical director, Founder, Adviser, Ravenna, Multimedia, National Human Genome Research Institute, Cleveland, International Baccalaureate, Anti-aging movement, Patient, Indian Medical Association, Internal medicine, YMCA, Research, Greater Cleveland, Alternative, Department, Medical device, Medicine, Pulmonology

As a seasoned medical doctor, Dr. Kara has garnered more than 30 years of experience proudly serving patients and their families.

Key Points: 
  • As a seasoned medical doctor, Dr. Kara has garnered more than 30 years of experience proudly serving patients and their families.
  • In 2017, Dr. Kara founded KaraMD, a line of digestive support, heart health, and anti-inflammatory supplements to support full-body health.
  • Following his training, Dr. Kara practiced at Ravenna Primary Care from 2001-2004 and then at Robinson Memorial Hospital from 2004-2005.
  • Dedicated to the medical community, Dr. Kara remains associated with the American Medical Association and the American Academy of Anti-Aging Medicine.

Enterin Announces Publication of Exciting Discoveries About the Enterin Nervous System

Retrieved on: 
Friday, November 19, 2021
Patient, Bupropion, Scientific Reports, Vagus nerve, Lists of diseases, Psychosis, CSO, Dopamine, McMaster University Medical School, Brain, Diabetes, Dementia, McMaster University, Sertraline, ENS, Human, Central nervous system, GI, Alzheimer's disease, Neurodegeneration, Sleep, Mouse, Norepinephrine, Neurogenesis, Selective serotonin reuptake inhibitor, Research, FRCP, Nervous system, Parkinson's disease, Obesity, GLOBE, Infection, Appetite, Enteric nervous system, Depression, Vagotomy, CNS, Fluoxetine, CMO, Pharmaceutical industry, Medical device, Medical imaging

Vast numbers of sensory signals originating in the gut are captured by the enteric nervous system (ENS) and conveyed to the brain via the vagus nerve.

Key Points: 
  • Vast numbers of sensory signals originating in the gut are captured by the enteric nervous system (ENS) and conveyed to the brain via the vagus nerve.
  • As a consequence, damage either to the ENS or the vagus nerve can have significant GI as well as neuropsychiatric consequences.
  • Serotonin (5-hydroxytryptamine; 5-HT) is an important neurotransmitter both in the central nervous system (CNS) and the ENS.
  • Serotonin is involved in GI-related functions such as neurogenesis, epithelial repair, GI secretions, and gut motility.

MIMEDX Reports Top-line Data from Two Late-Stage Musculoskeletal Trials with Proprietary Amniotic Tissue Technology

Retrieved on: 
Monday, September 13, 2021
Patient, Khaneqah Bala va Pain, Annual report, Physician, Gauge (instrument), Review, Research, Health, Science, Forward-looking statement, Research and development, RICE, U.S. Securities and Exchange Commission, WOMAC, Șaeș, KOA, Compression, Randomized controlled trial, GLOBE, Diagnosis, Good tissue practice, Security (finance), Food, Sterilization, Incidence, FDA, AES, Tissue, Ice, BLA, Plantar fasciitis, Osteoarthritis, Biologics license application, Time, Safety, Development, Regenerative medicine, Person, Knee, McMaster University Medical School, Kellgren, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Trial of the century, Company, Cohort study, Clinical trial, Hotel manager, Industry, VAS, Injection, Allotransplantation, Population, Risk, File, Pharmaceutical industry, Medical imaging

MARIETTA, Ga., Sept. 13, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced top-line results from two late-stage musculoskeletal clinical trials of the Company’s micronized dehydrated Human Amnion Chorion Membrane (mdHACM): a Phase 2B clinical trial for the treatment of Knee Osteoarthritis (KOA) and a Phase 3 clinical trial for the treatment of Plantar Fasciitis (PF).

Key Points: 
  • On behalf of MIMEDX, I extend our gratitude to all the patients, families, and physicians who participated in these important and informative trials.
  • MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.
  • We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION process.
  • We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts.